Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07017790

Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas

Amino Acid PET Imaging to Assess the Efficacy of IDH Inhibitor Treatments for Patients With Refractory IDH Mutated Gliomas

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
22 (estimated)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas

Detailed description

Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas In fact, this study will allow us to assess, using Rano 1.0 criteria for PET and Rano 2.0 criteria for MRI, which of the two examinations is most effective in assessing the efficacy of anti-IDH treatment patients with refractory IDH-mutated gliomas.

Conditions

Interventions

TypeNameDescription
OTHERAmino-acid PETPatients received 18-fluoroDopa then a PET exam

Timeline

Start date
2025-06-30
Primary completion
2025-07-01
Completion
2025-08-30
First posted
2025-06-12
Last updated
2025-06-12

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT07017790. Inclusion in this directory is not an endorsement.

Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas (NCT07017790) · Clinical Trials Directory